Equity Research Pharmaceutical Preparations

Should You Buy InMed Pharmaceuticals Inc. Stock in 2026?

By CirclFi Research Team · · 11/13 models active

According to the CirclFi Deep Alpha Valuation Engine, InMed Pharmaceuticals Inc. (INM) scores 5.4/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $1.54, our multi-model valuation analyzes whether the market has already discounted these weaknesses.

The short answer: 7 of 11 CirclFi valuation models project upside for InMed Pharmaceuticals Inc. (INM) at $1.54 — the model consensus leans bullish, with a Quality Score of 5.4/10 and Value-Trap risk of 39/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 7 of 11 models see upside — majority bullish
  • Quality Score: 5.4/10 — Moderate — mixed signals
  • Value Trap Risk: 39/100 — Low — manageable risk
  • Fair Value Range: $0.25 – $3.86 (1429% spread)

Bullish Models

7 / 11

Bearish Models

4 / 11

Quality Score

5.4 /10

Moderate — mixed signals

Value Trap Risk

39 /100
Low

Low — manageable risk

Model Consensus

11 /13
Active Models

Avg. confidence: 26%

Investment Thesis

The Bull Case

Target: $3.86 (+150.9% upside)

  • According to the CirclFi Deep Alpha Valuation Engine, 7 of 11 models identify upside from $1.54 to a composite fair value of $2.15, indicating the market hasn't fully priced in InMed Pharmaceuticals Inc.'s earnings power.
  • According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model targets a fair value of $3.86 (+150.9%), anchoring the bull case with a methodology that evaluates base, bull, and bear scenarios simultaneously.
  • Industry tailwind: regulatory pathway clarity could provide meaningful support for InMed Pharmaceuticals Inc.'s revenue and margin trajectory in the Pharmaceutical Preparations space.

The Bear Case

Target: $0.25 (-83.6%)

  • According to the CirclFi Quality of Company (QOC) framework, InMed Pharmaceuticals Inc.'s score of 5.4/10 signals fundamental weaknesses that could undermine the investment thesis.
  • According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.25 (-83.6%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +234.5% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
  • Industry headwind: clinical trial failure represents a meaningful risk for InMed Pharmaceuticals Inc. and its Pharmaceutical Preparations peers.

Peer Benchmarking

CPRX Catalyst Pharmaceuti
10.0
HRMY Harmony Biosciences
10.0
NVO Novo Nordisk A/S
10.0
SIGA SIGA Technologies In
10.0
UTHR United Therapeutics
10.0

See full Pharmaceutical Preparations rankings →

Valuation Divergence

Spread

1429%

Fair Value Range

$0.25 – $3.86

A 1429% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

First Chicago

$3.86 (+150.9%)

Most Bearish

ML-RIV

$0.25 (-83.6%)

Key Risk Factors

Model Disagreement

1429% spread signals high variance in projections.

Macro/Sector Risk

Pharmaceutical Preparations headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View INM Data Page →

The Bottom Line

InMed Pharmaceuticals Inc. leans positive in our analysis — 7/11 models bullish, composite fair value of $2.15 vs. $1.54, QOC 5.4/10. The case is constructive but not overwhelming, and the 3 dissenting models shouldn't be dismissed. Position sizing should reflect this moderate conviction level.

These are quantitative model outputs, not investment recommendations. InMed Pharmaceuticals Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy INM stock right now?

Based on CirclFi's multi-model analysis, 7 of 11 models see upside for INM at $1.54. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 5.4/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in InMed Pharmaceuticals Inc.?

Key risks include: wide model disagreement (1429% spread), signaling high uncertainty; general market and sector-specific risks affecting Pharmaceutical Preparations companies. Always diversify and consult a financial advisor.

How does INM compare to its competitors?

Among Pharmaceutical Preparations peers, INM holds a Quality Score of 5.4/10. Comparable companies include CPRX (QOC 10.0), HRMY (QOC 10.0), NVO (QOC 10.0). The relative ranking helps investors identify whether INM offers better fundamental quality than alternatives in the same sector.

Is INM a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. INM's Quality Score of 5.4/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy INM at?

CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $0.25 to $3.86. At $1.54, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for INM.

View INM Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →